Admelog FDA Approval History
Admelog (insulin lispro) is a follow-on rapid-acting human insulin analog (referenced to Humalog) for the treatment of patients with type 1 and type 2 diabetes.
Development Timeline for Admelog
|Dec 11, 2017||FDA Approves Admelog (insulin lispro) Rapid-Acting "Follow-On" Insulin Product to Treat Diabetes|
|Sep 1, 2017||Sanofi Receives Tentative FDA Approval of Admelog (insulin lispro injection) 100 units/mL|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.